EMV

EMVISION FPO [EMV]
EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia.
Healthcare · ASX Small Cap
$1.8000 -2.2%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 4 consecutive scansFirst seen: 2026-03-03
Get alerts when EMV triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track EMV — Free

Active Signals

Bullish Signals

  • Trading above both moving averages — the trend is your friend here
  • Trading above the 200-day average — the long-term trend is on your side
  • Strong cash runway (11 quarters)
  • Strong revenue growth (+188%)
  • EPS estimates revised downward (-10pts)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +188% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.69%/day)
  • RBA hiking (-3pts)
  • Trial readout: (est. 2026-11-01)

Risk Signals

  • Deeply negative margins (-100%)
  • Not enough chatter to gauge sentiment — defaulting to neutral

Expected next for EMV

31 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 24 Oct to 7 Nov
The last 8 moved EMV -0.7% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE emu Regional Benefits Study Advancing
NONE FY26 Results Presentation
NONE Appendix 4G & Corporate Governance Statement
HIGH emu Pivotal Trial Recruitment Surpasses 200 Patients
LOW Appendix 4E & Annual Report to 30 June 2026

Recent ASX Announcements

2026-09-02 emu Regional Benefits Study Advancing PRICE SENSITIVE
2026-08-30 emu Pivotal Trial Recruitment Surpasses 200 Patients PRICE SENSITIVE
2026-08-23 FY26 Results Presentation
2026-08-23 Appendix 4G & Corporate Governance Statement
2026-08-23 Appendix 4E & Annual Report to 30 June 2026 PRICE SENSITIVE

Key Metrics

$167.8M
Market Cap
38K
Avg Volume
1.0x
Vol Ratio
$1.47 — $2.43
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-66.4%
ROE
-99.5%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 66%
LLeader vs LaggardpassRS: 11
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:EMV vs NUZEMV vs IPDEMV vs HIQ
Share this analysis

Track EMV and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required